AlphaCrest Capital Management’s Heron Therapeutics HRTX Stock Holding History

AlphaCrest Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,755	Closed	-$244K	–	1323
2021 Q4	$244K	Buy	+26,755	New	+$273K	0.01%	1300
2021 Q2	–	Sell	-19,123	Closed	-$310K	–	1280
2021 Q1	$310K	Buy	19,123 +8,886	+87%	+$158K	0.02%	1012
2020 Q4	$217K	Buy	+10,237	New	+$178K	0.02%	1050
2020 Q3	–	Sell	-12,494	Closed	-$184K	–	1140
2020 Q2	$184K	Sell	12,494 -20,387	-62%	-$335K	0.03%	852
2020 Q1	$386K	Buy	32,881 +18,909	+135%	+$355K	0.05%	683
2019 Q4	$328K	Buy	+13,972	New	+$309K	0.03%	1013

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

AlphaCrest Capital Management's HRTX Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 26,755 shares — an estimated $244K sold.

AlphaCrest Capital Management first reported a position in HRTX in Q4 2019 and held it in 6 quarters. The position peaked at $386K in Q1 2020. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

AlphaCrest Capital Management reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 26,755 Heron Therapeutics shares in Q1 2022, an estimated $244K.
AlphaCrest Capital Management first reported a position in Heron Therapeutics in Q4 2019 and held it in 6 quarters.
AlphaCrest Capital Management's Heron Therapeutics position peaked at $386K in Q1 2020.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.